论文部分内容阅读
临床上常用的以癌胚抗原(CEA)和甲胎蛋白(AFP)为代表的第一代肿瘤标志对癌症的诊断和动态监测有重要意义,但发现肿瘤特异的新抗原是很困难的。最近,单克隆抗体技术有了突破性的进展,抗癌细胞表面抗原的单克隆抗体已研制成功。C A19-9和CA125等第二代肿瘤标志相继问世,核素标记的单克隆抗体能选择地结合癌的表面抗原。是诊断癌症的
Clinically used first-line tumor markers represented by carcinoembryonic antigen (CEA) and alpha-fetoprotein (AFP) are important for the diagnosis and dynamic monitoring of cancer, but it is difficult to find tumor-specific new antigens. Recently, monoclonal antibody technology has made breakthrough progress, and monoclonal antibodies against cancer cell surface antigens have been successfully developed. The second generation of tumor markers, such as C19-19 and CA125, came into being one after another. Radiolabeled monoclonal antibodies selectively bind to the surface antigen of the cancer. Is to diagnose cancer